Cardiovascular disease treatment is entering a new era. Doctors are no longer limited to symptom control alone. With better diagnosis, genetic testing, and targeted drugs, hospitals can now design more precise treatment plans for complex heart conditions.
At Shulan Hospital, this progress is already helping patients with difficult cardiovascular diseases. One important example is the treatment of hypertrophic obstructive cardiomyopathy, also known as HOCM.
This condition can block blood flow from the heart. It may cause chest discomfort, shortness of breath, low blood pressure, heart failure symptoms, and serious long-term risks. For some patients, conventional medication does not provide enough relief.
Shulan Hospital’s Department of Cardiology has explored a more precise approach. Through targeted therapy and multidisciplinary care, the team helped a patient with severe HOCM regain stability and quality of life.
What Is Hypertrophic Obstructive Cardiomyopathy?
Hypertrophic obstructive cardiomyopathy is a heart muscle disease. In this condition, part of the heart muscle becomes abnormally thick.
The thickened muscle can narrow the left ventricular outflow tract. This pathway allows blood to leave the heart and enter the body. When the pathway becomes blocked, the heart must work harder to pump blood.
Patients may experience fatigue, dizziness, chest tightness, shortness of breath, or symptoms of heart failure. Some patients may also have a family history, because hypertrophic cardiomyopathy can be related to genetic factors.
A key measurement in HOCM is the left ventricular outflow tract pressure gradient. A high gradient means the obstruction is serious. Doctors use echocardiography and other tests to evaluate this problem.
A Complex Case at Shulan Hospital
Mr. Jiang, a 68-year-old patient, had lived with hypertrophic obstructive cardiomyopathy for many years. More than ten years ago, he began to show symptoms of heart failure.
Six years ago, doctors implanted a cardiac resynchronization therapy pacemaker to support his heart function. However, his condition later worsened.
When he came to Shulan Hospital, the cardiology team performed a detailed evaluation. The results showed a serious obstruction. His myocardial thickness reached 26 millimeters. His left ventricular outflow tract pressure gradient reached 112 mmHg.
These numbers showed that his heart had great difficulty sending blood into the body.
Conventional treatment had limited effect. His blood pressure was too low, so doctors could not simply increase the medication dose. The team also considered chemical ablation. However, angiography showed that he did not have a suitable target vessel.
The treatment plan reached a difficult point.
Targeted Therapy Brought New Hope
At that time, a new targeted drug for hypertrophic obstructive cardiomyopathy was about to become available in Hangzhou. After discussion with the patient’s family, the cardiology team decided to try this treatment once it entered the market.
The team used the medication carefully. Doctors started with the minimum effective dose and monitored the patient closely.
One month later, the follow-up results showed clear improvement. His left ventricular outflow tract pressure gradient dropped from 112 mmHg to around 60 mmHg. His peripheral blood pressure also returned to a more stable level.
The patient felt more energetic. His family also noticed a visible change in his daily condition.
After that, Mr. Jiang returned to the hospital every four weeks for follow-up. Doctors used echocardiography, blood tests, and other indicators to monitor his progress. His cardiac function remained stable, and the obstruction improved.
Why Targeted Therapy Matters in Cardiology
Traditional treatment for hypertrophic cardiomyopathy often focuses on reducing symptoms. Doctors may use beta-blockers and other medications to slow the heart rate and reduce the workload of the heart.
Some patients may need septal reduction therapy or surgery. However, these options may carry higher risk, especially for older patients or people with multiple health problems.
Targeted therapy offers another direction. It focuses more directly on the disease mechanism. In hypertrophic cardiomyopathy, certain genetic and protein-level abnormalities can affect heart muscle contraction.
By acting on specific targets, new therapies may help reduce obstruction and improve cardiac function. This does not mean every patient can use targeted drugs. Doctors still need careful diagnosis, risk evaluation, and long-term monitoring.
But for selected patients, targeted therapy may provide new possibilities.
Multidisciplinary Care for a High-Risk Patient
Mr. Jiang’s treatment was complex because he did not only have heart disease. He also had long-term liver disease related to schistosomiasis, which had progressed to cirrhosis.
Cirrhosis increased his risk of esophageal and gastric variceal bleeding. After his blood pressure improved, the pressure in fragile vessels also became a concern.
In April, he had an episode of gastrointestinal bleeding. Doctors controlled the condition with conservative treatment. Later, he developed a more serious bleeding event and hemorrhagic shock.
The situation became critical.
Shulan Hospital quickly organized a multidisciplinary consultation. The team included specialists from cardiology, infectious diseases, interventional vascular surgery, gastroenterology, and anesthesiology.
After careful assessment, the team decided to perform an emergency TIPS procedure. TIPS stands for transjugular intrahepatic portosystemic shunt. This procedure helps reduce portal venous pressure and control variceal bleeding.
The operation carried high risk because the patient had recently improved heart function and was in shock. The team monitored his heart rate, blood pressure, and vital signs throughout the procedure.
After more than two hours, the operation achieved successful hemostasis.
Recovery and Long-Term Management
After surgery, the infectious diseases team created a new anti-infection plan. The goal was to reduce complications related to cirrhosis, weak immunity, and postoperative recovery.
The team also worked to prevent hepatic encephalopathy and cardiac insufficiency. After more than one month of rehabilitation, the patient’s gastrointestinal bleeding was controlled.
This case shows why multidisciplinary care is important. A patient with complex disease rarely needs only one treatment. Heart disease, liver disease, bleeding risk, infection risk, and rehabilitation all affect the final outcome.
For Mr. Jiang, targeted therapy improved the core cardiac problem. Then multidisciplinary care helped him survive a later emergency.
Precision Diagnosis Comes Before Precision Treatment
Targeted therapy does not fit every patient. Before doctors use this kind of treatment, they need a precise diagnosis.
This may include blood tests, cardiac imaging, echocardiography, genetic testing, and specialist evaluation. Doctors need to understand the cause of the disease before they choose a therapy.
In cardiovascular medicine, this approach is becoming more important. Some patients need protein-level targeted drugs. Others may benefit from RNA-level therapies or future gene-level treatments.
This shift may change how doctors manage inherited cardiovascular diseases, familial hyperlipidemia, and certain types of cardiomyopathy.
Shulan Hospital’s Approach to Advanced Cardiovascular Care
Shulan Hospital’s cardiology team focuses on both advanced treatment and whole-person care. The hospital does not only treat one symptom. It evaluates the patient’s full condition and builds a coordinated plan.
For patients with complex heart disease, this approach can be especially valuable. They may need cardiology, imaging, interventional treatment, intensive care, hepatology, infectious disease care, and rehabilitation support.
The case of Mr. Jiang reflects this model. It combines targeted cardiovascular therapy, careful monitoring, emergency intervention, and multidisciplinary cooperation.
Conclusion
Targeted therapy for hypertrophic obstructive cardiomyopathy is changing the future of cardiovascular care. It gives selected patients a new option when conventional treatment is not enough.
At Shulan Hospital, the successful management of a complex HOCM case shows the value of precision medicine. It also shows the importance of multidisciplinary care for patients with multiple high-risk conditions.
For patients with unexplained heart failure symptoms, chest discomfort, shortness of breath, or a family history of cardiomyopathy, early evaluation is important. A timely diagnosis can open the door to more personalized treatment options.
As cardiovascular medicine continues to advance, targeted therapy may help more patients achieve better outcomes and a better quality of life.